Download PDF
Thromb Haemost 2022; 122(02): 181-195
DOI: 10.1055/s-0041-1730375
Review Article

MicroRNA as Biomarkers for Platelet Function and Maturity in Patients with Cardiovascular Disease

Oliver Buchhave Pedersen 
1   Department of Clinical Biochemistry, Thrombosis and Haemostasis Research Unit, Aarhus University Hospital, Aarhus, Denmark
2   Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
,
Erik Lerkevang Grove 
2   Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
3   Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark
,
Steen Dalby Kristensen
2   Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
3   Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark
,
Peter H. Nissen
1   Department of Clinical Biochemistry, Thrombosis and Haemostasis Research Unit, Aarhus University Hospital, Aarhus, Denmark
3   Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark
,
Anne-Mette Hvas 
1   Department of Clinical Biochemistry, Thrombosis and Haemostasis Research Unit, Aarhus University Hospital, Aarhus, Denmark
3   Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark
› Author Affiliations Funding We received financial support from the Department of Clinical Biochemistry, Aarhus University Hospital.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Patients with cardiovascular disease (CVD) are at increased risk of suffering myocardial infarction. Platelets are key players in thrombus formation and, therefore, antiplatelet therapy is crucial in the treatment and prevention of CVD. MicroRNAs (miRs) may hold the potential as biomarkers for platelet function and maturity. This systematic review was conducted using the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). To identify studies investigating the association between miRs and platelet function and maturity in patients with CVD, PubMed and Embase were searched on October 13 and December 13, 2020 without time boundaries. Risk of bias was evaluated using a standardized quality assessment tool. Of the 16 included studies, 6 studies were rated “good” and 10 studies were rated “fair.” In total, 45 miRs correlated significantly with platelet function or maturity (rho ranging from –0.68 to 0.38, all p < 0.05) or differed significantly between patients with high platelet reactivity and patients with low platelet reactivity (p-values ranging from 0.0001 to 0.05). Only four miRs were investigated in more than two studies, namely miR-223, miR-126, miR-21 and miR-150. Only one study reported on the association between miRs and platelet maturity. In conclusion, a total of 45 miRs were associated with platelet function or maturity in patients with CVD, with miR-223 and miR-126 being the most frequently investigated. However, the majority of the miRs were only investigated in one study. More data are needed on the potential use of miRs as biomarkers for platelet function and maturity in CVD patients.

Keywords

MicroRNAs - biomarker - platelet function test - prognosis - cardiovascular disease

Supplementary Material



Publication History

Received: 06 February 2021

Accepted: 07 April 2021

Article published online:
06 June 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 WHO. Cardiovascular diseases (CVDs). 2020 . Available at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
    Search in Google Scholar
  • 2 Sjögren M, Almgren P, Melander O. Polygenetic risk for coronary artery disease increases hospitalization burden and mortality. Int J Cardiol Heart Vasc 2019; 24: 100391
    PubMedSearch in Google Scholar
  • 3 Adelborg K, Grove EL, Sundbøll J, Laursen M, Schmidt M. Sixteen-year nationwide trends in antithrombotic drug use in Denmark and its correlation with landmark studies. Heart 2016; 102 (23) 1883-1889
    CrossrefPubMedSearch in Google Scholar
  • 4 Freynhofer MK, Bruno V, Wojta J, Huber K. The role of platelets in athero-thrombotic events. Curr Pharm Des 2012; 18 (33) 5197-5214
    CrossrefPubMedSearch in Google Scholar
  • 5 Grove EL, Würtz M, Thomas MR, Kristensen SD. Antiplatelet therapy in acute coronary syndromes. Expert Opin Pharmacother 2015; 16 (14) 2133-2147
    CrossrefPubMedSearch in Google Scholar
  • 6 Gremmel T, Frelinger III AL, Michelson AD. Platelet physiology. Semin Thromb Hemost 2016; 42 (03) 191-204
    Thieme ConnectPubMedSearch in Google Scholar
  • 7 Halvorsen S, Andreotti F, ten Berg JM. et al. Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis. J Am Coll Cardiol 2014; 64 (03) 319-327
    CrossrefPubMedSearch in Google Scholar
  • 8 Patrono C, Morais J, Baigent C. et al. Antiplatelet agents for the treatment and prevention of coronary atherothrombosis. J Am Coll Cardiol 2017; 70 (14) 1760-1776
    CrossrefPubMedSearch in Google Scholar
  • 9 Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997; 23 (04) 349-356
    Thieme ConnectPubMedSearch in Google Scholar
  • 10 Larsen SB, Grove EL, Neergaard-Petersen S, Würtz M, Hvas AM, Kristensen SD. Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease. PLoS One 2015; 10 (05) e0126767
    CrossrefPubMedSearch in Google Scholar
  • 11 Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167 (15) 1593-1599
    CrossrefPubMedSearch in Google Scholar
  • 12 Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336 (7637): 195-198
    CrossrefPubMedSearch in Google Scholar
  • 13 Guirgis M, Thompson P, Jansen S. Review of aspirin and clopidogrel resistance in peripheral arterial disease. J Vasc Surg 2017; 66 (05) 1576-1586
    CrossrefPubMedSearch in Google Scholar
  • 14 Rocca B, Dragani A, Pagliaccia F. Identifying determinants of variability to tailor aspirin therapy. Expert Rev Cardiovasc Ther 2013; 11 (03) 365-379
    CrossrefPubMedSearch in Google Scholar
  • 15 Würtz M, Grove EL. Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance. Curr Pharm Des 2012; 18 (33) 5344-5361
    CrossrefPubMedSearch in Google Scholar
  • 16 Freynhofer MK, Gruber SC, Grove EL, Weiss TW, Wojta J, Huber K. Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing. Thromb Haemost 2015; 114 (03) 459-468
    Thieme ConnectPubMedSearch in Google Scholar
  • 17 Cesari F, Marcucci R, Caporale R. et al. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost 2008; 99 (05) 930-935
    Thieme ConnectPubMedSearch in Google Scholar
  • 18 Guthikonda S, Alviar CL, Vaduganathan M. et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 2008; 52 (09) 743-749
    CrossrefPubMedSearch in Google Scholar
  • 19 McBane II RD, Gonzalez C, Hodge DO, Wysokinski WE. Propensity for young reticulated platelet recruitment into arterial thrombi. J Thromb Thrombolysis 2014; 37 (02) 148-154
    CrossrefPubMedSearch in Google Scholar
  • 20 Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature 2008; 455 (7209): 64-71
    Search in Google Scholar
  • 21 Arroyo AB, de Los Reyes-García AM, Teruel-Montoya R, Vicente V, González-Conejero R, Martínez C. microRNAs in the haemostatic system: more than witnesses of thromboembolic diseases?. Thromb Res 2018; 166: 1-9
    CrossrefPubMedSearch in Google Scholar
  • 22 Lim LP, Lau NC, Garrett-Engele P. et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433 (7027): 769-773
    CrossrefPubMedSearch in Google Scholar
  • 23 Rowley JW, Schwertz H, Weyrich AS. Platelet mRNA: the meaning behind the message. Curr Opin Hematol 2012; 19 (05) 385-391
    CrossrefPubMedSearch in Google Scholar
  • 24 Lu J, Guo S, Ebert BL. et al. MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev Cell 2008; 14 (06) 843-853
    CrossrefPubMedSearch in Google Scholar
  • 25 Girardot M, Pecquet C, Boukour S. et al. miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets. Blood 2010; 116 (03) 437-445
    CrossrefPubMedSearch in Google Scholar
  • 26 Tran JQD, Pedersen OH, Larsen ML. et al. Platelet microRNA expression and association with platelet maturity and function in patients with essential thrombocythemia. Platelets 2020; 31 (03) 365-372
    CrossrefPubMedSearch in Google Scholar
  • 27 Landry P, Plante I, Ouellet DL, Perron MP, Rousseau G, Provost P. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol 2009; 16 (09) 961-966
    Search in Google Scholar
  • 28 Liberati A, Altman DG, Tetzlaff J. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6 (07) e1000100
    CrossrefPubMedSearch in Google Scholar
  • 29 Martin JF, Trowbridge EA, Salmon G, Plumb J. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 1983; 32 (05) 443-460
    CrossrefPubMedSearch in Google Scholar
  • 30 The National Heart LaBIotNIoH. Study Quality Assessment Tools. 2013 . Available at: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
    Search in Google Scholar
  • 31 Li L, Wu F, Xie Y. et al. MiR-202-3p inhibits foam cell formation and is associated with coronary heart disease risk in a Chinese population. Int Heart J 2020; 61 (01) 153-159
    CrossrefPubMedSearch in Google Scholar
  • 32 Xie W, Yin Q, Zhang M, Li S, Chen S. Leukocyte miR-223-3p is not associated with altered platelet responses to clopidogrel in patients with coronary artery disease. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2018; 43 (04) 421-427
    PubMedSearch in Google Scholar
  • 33 Becker KC, Kwee LC, Neely ML. et al. Circulating MicroRNA profiling in non-ST elevated coronary artery syndrome highlights genomic associations with serial platelet reactivity measurements. Sci Rep 2020; 10 (01) 6169
    CrossrefPubMedSearch in Google Scholar
  • 34 Li S, Guo LZ, Kim MH, Han JY, Serebruany V. Platelet microRNA for predicting acute myocardial infarction. J Thromb Thrombolysis 2017; 44 (04) 556-564
    CrossrefPubMedSearch in Google Scholar
  • 35 Binderup HG, Houlind K, Madsen JS, Brasen CL. Aspirin resistance may be identified by miR-92a in plasma combined with platelet distribution width. Clin Biochem 2016; 49 (15) 1167-1172
    CrossrefPubMedSearch in Google Scholar
  • 36 Chen S, Qi X, Chen H. et al. Expression of miRNA-26a in platelets is associated with clopidogrel resistance following coronary stenting. Exp Ther Med 2016; 12 (01) 518-524
    CrossrefPubMedSearch in Google Scholar
  • 37 Chen YC, Lin FY, Lin YW. et al. Platelet MicroRNA 365-3p expression correlates with high on-treatment platelet reactivity in coronary artery disease patients. Cardiovasc Drugs Ther 2019; 33 (02) 129-137
    CrossrefPubMedSearch in Google Scholar
  • 38 Chyrchel B, Totoń-Żurańska J, Kruszelnicka O. et al. Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report. Platelets 2015; 26 (06) 593-597
    CrossrefPubMedSearch in Google Scholar
  • 39 Ding T, Zeng X, Cheng B. et al. Platelets in acute coronary syndrome patients with high platelet reactivity after dual antiplatelet therapy exhibit upregulation of miR-204-5p. Ann Clin Lab Sci 2019; 49 (05) 619-631
    PubMedSearch in Google Scholar
  • 40 Jäger B, Stojkovic S, Haller PM. et al. Course of platelet miRNAs after cessation of P2Y12 antagonists. Eur J Clin Invest 2019; 49 (08) e13149
    CrossrefPubMedSearch in Google Scholar
  • 41 Kaudewitz D, Skroblin P, Bender LH. et al. Association of MicroRNAs and YRNAs with platelet function. Circ Res 2016; 118 (03) 420-432
    CrossrefPubMedSearch in Google Scholar
  • 42 Shi R, Ge L, Zhou X. et al. Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity. Thromb Res 2013; 131 (06) 508-513
    CrossrefPubMedSearch in Google Scholar
  • 43 Peng L, Liu J, Qin L. et al. Interaction between platelet-derived microRNAs and CYP2C19*2 genotype on clopidogrel antiplatelet responsiveness in patients with ACS. Thromb Res 2017; 157: 97-102
    CrossrefPubMedSearch in Google Scholar
  • 44 Tang QJ, Lei HP, Wu H. et al. Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy. Acta Pharmacol Sin 2019; 40 (02) 208-215
    CrossrefPubMedSearch in Google Scholar
  • 45 Zhang YY, Zhou X, Ji WJ. et al. Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome. J Thromb Thrombolysis 2014; 38 (01) 65-72
    CrossrefPubMedSearch in Google Scholar
  • 46 Zufferey A, Ibberson M, Reny JL. et al. New molecular insights into modulation of platelet reactivity in aspirin-treated patients using a network-based approach. Hum Genet 2016; 135 (04) 403-414
    CrossrefPubMedSearch in Google Scholar
  • 47 Faraldi M, Gomarasca M, Sansoni V, Perego S, Banfi G, Lombardi G. Normalization strategies differently affect circulating miRNA profile associated with the training status. Sci Rep 2019; 9 (01) 1584
    CrossrefPubMedSearch in Google Scholar
  • 48 Fejes Z, Póliska S, Czimmerer Z. et al. Hyperglycaemia suppresses microRNA expression in platelets to increase P2RY12 and SELP levels in type 2 diabetes mellitus. Thromb Haemost 2017; 117 (03) 529-542
    Thieme ConnectPubMedSearch in Google Scholar
  • 49 Singh S, de Ronde MWJ, Kok MGM. et al. MiR-223-3p and miR-122-5p as circulating biomarkers for plaque instability. Open Heart 2020; 7 (01) e001223
    Search in Google Scholar
  • 50 Pan Y, Liang H, Liu H. et al. Platelet-secreted microRNA-223 promotes endothelial cell apoptosis induced by advanced glycation end products via targeting the insulin-like growth factor 1 receptor. J Immunol 2014; 192 (01) 437-446
    CrossrefPubMedSearch in Google Scholar
  • 51 Kaur A, Mackin ST, Schlosser K. et al. Systematic review of microRNA biomarkers in acute coronary syndrome and stable coronary artery disease. Cardiovasc Res 2020; 116 (06) 1113-1124
    CrossrefPubMedSearch in Google Scholar
  • 52 Kahner BN, Shankar H, Murugappan S, Prasad GL, Kunapuli SP. Nucleotide receptor signaling in platelets. J Thromb Haemost 2006; 4 (11) 2317-2326
    CrossrefPubMedSearch in Google Scholar
  • 53 Wang S, Aurora AB, Johnson BA. et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008; 15 (02) 261-271
    CrossrefPubMedSearch in Google Scholar
  • 54 Fish JE, Santoro MM, Morton SU. et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008; 15 (02) 272-284
    CrossrefPubMedSearch in Google Scholar
  • 55 Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A 2008; 105 (05) 1516-1521
    CrossrefPubMedSearch in Google Scholar
  • 56 Meng Q, Wang W, Yu X. et al. Upregulation of MicroRNA-126 contributes to endothelial progenitor cell function in deep vein thrombosis via its target PIK3R2. J Cell Biochem 2015; 116 (08) 1613-1623
    CrossrefPubMedSearch in Google Scholar
  • 57 Jansen F, Yang X, Hoelscher M. et al. Endothelial microparticle-mediated transfer of MicroRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. Circulation 2013; 128 (18) 2026-2038
    CrossrefPubMedSearch in Google Scholar
  • 58 Schober A, Nazari-Jahantigh M, Wei Y. et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med 2014; 20 (04) 368-376
    CrossrefPubMedSearch in Google Scholar
  • 59 Dai B, Wang F, Nie X. et al. The cell type-specific functions of miR-21 in cardiovascular diseases. Front Genet 2020; 11: 563166
    CrossrefPubMedSearch in Google Scholar
  • 60 Raitoharju E, Oksala N, Lehtimäki T. MicroRNAs in the atherosclerotic plaque. Clin Chem 2013; 59 (12) 1708-1721
    CrossrefPubMedSearch in Google Scholar
  • 61 Weber M, Baker MB, Moore JP, Searles CD. MiR-21 is induced in endothelial cells by shear stress and modulates apoptosis and eNOS activity. Biochem Biophys Res Commun 2010; 393 (04) 643-648
    CrossrefPubMedSearch in Google Scholar
  • 62 Suárez Y, Fernández-Hernando C, Pober JS, Sessa WC. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res 2007; 100 (08) 1164-1173
    CrossrefPubMedSearch in Google Scholar
  • 63 Ji R, Cheng Y, Yue J. et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res 2007; 100 (11) 1579-1588
    CrossrefPubMedSearch in Google Scholar
  • 64 Tano N, Kim HW, Ashraf M. microRNA-150 regulates mobilization and migration of bone marrow-derived mononuclear cells by targeting Cxcr4. PLoS One 2011; 6 (10) e23114
    CrossrefPubMedSearch in Google Scholar
  • 65 Murphy AJ, Bijl N, Yvan-Charvet L. et al. Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis. Nat Med 2013; 19 (05) 586-594
    CrossrefPubMedSearch in Google Scholar
  • 66 Farina NH, Wood ME, Perrapato SD. et al. Standardizing analysis of circulating microRNA: clinical and biological relevance. J Cell Biochem 2014; 115 (05) 805-811
    CrossrefPubMedSearch in Google Scholar
  • 67 Zampetaki A, Mayr M. Analytical challenges and technical limitations in assessing circulating miRNAs. Thromb Haemost 2012; 108 (04) 592-598
    Thieme ConnectPubMedSearch in Google Scholar
  • 68 Willeit P, Zampetaki A, Dudek K. et al. Circulating microRNAs as novel biomarkers for platelet activation. Circ Res 2013; 112 (04) 595-600
    CrossrefPubMedSearch in Google Scholar
  • 69 Kaudewitz D, Lee R, Willeit P. et al. Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease. Thromb Haemost 2013; 110 (03) 609-615
    Thieme ConnectPubMedSearch in Google Scholar
  • 70 Gidlöf O, Andersson P, van der Pals J, Götberg M, Erlinge D. Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. Cardiology 2011; 118 (04) 217-226
    CrossrefPubMedSearch in Google Scholar
  • 71 Willeit P, Skroblin P, Moschen AR. et al. Circulating MicroRNA-122 Is associated with the risk of new-onset metabolic syndrome and type 2 diabetes. Diabetes 2017; 66 (02) 347-357
    CrossrefPubMedSearch in Google Scholar
  • 72 Boeckel JN, Thomé CE, Leistner D, Zeiher AM, Fichtlscherer S, Dimmeler S. Heparin selectively affects the quantification of microRNAs in human blood samples. Clin Chem 2013; 59 (07) 1125-1127
    CrossrefPubMedSearch in Google Scholar
  • 73 Grove EL, Hvas AM, Johnsen HL. et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010; 103 (06) 1245-1253
    Thieme ConnectPubMedSearch in Google Scholar